Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Wilms’ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease
Vishwaraj Sontake, Rajesh K. Kasam, Debora Sinner, Thomas R. Korfhagen, Geereddy B. Reddy, Eric S. White, Anil G. Jegga, Satish K. Madala
Vishwaraj Sontake, Rajesh K. Kasam, Debora Sinner, Thomas R. Korfhagen, Geereddy B. Reddy, Eric S. White, Anil G. Jegga, Satish K. Madala
View: Text | PDF
Research Article Pulmonology

Wilms’ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease

  • Text
  • PDF
Abstract

Wilms’ tumor 1 (WT1) is a critical transcriptional regulator of mesothelial cells during lung development but is downregulated in postnatal stages and adult lungs. We recently showed that WT1 is upregulated in both mesothelial cells and mesenchymal cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a fatal fibrotic lung disease. Although WT1-positive cell accumulation leading to severe fibrotic lung disease has been studied, the role of WT1 in fibroblast activation and pulmonary fibrosis remains elusive. Here, we show that WT1 functions as a positive regulator of fibroblast activation, including fibroproliferation, myofibroblast transformation, and extracellular matrix (ECM) production. Chromatin immunoprecipitation experiments indicate that WT1 binds directly to the promoter DNA sequence of α-smooth muscle actin (αSMA) to induce myofibroblast transformation. In support, the genetic lineage tracing identifies WT1 as a key driver of mesothelial-to-myofibroblast and fibroblast-to-myofibroblast transformation. Importantly, the partial loss of WT1 was sufficient to attenuate myofibroblast accumulation and pulmonary fibrosis in vivo. Further, our coculture studies show that WT1 upregulation leads to non–cell autonomous effects on neighboring cells. Thus, our data uncovered a pathogenic role of WT1 in IPF by promoting fibroblast activation in the peripheral areas of the lung and as a target for therapeutic intervention.

Authors

Vishwaraj Sontake, Rajesh K. Kasam, Debora Sinner, Thomas R. Korfhagen, Geereddy B. Reddy, Eric S. White, Anil G. Jegga, Satish K. Madala

×

Figure 2

WT1-lineage cells are the major source of mesenchymal cells in subpleural fibrotic lesions in vivo.

Options: View larger image (or click on image) Download as PowerPoint
WT1-lineage cells are the major source of mesenchymal cells in subpleura...
(A) Schematic diagram of treatments with tamoxifen and Dox. For pretamoxifen treatments (Pre-Tam), control, or TGFα/WT1CreERT2/mTmG mice were induced with tamoxifen, and 1 week later, pulmonary fibrosis was induced by administering Dox in food for 4 weeks. For Pre- and posttamoxifen treatments (Pre/Post-Tam), TGFα/WT1CreERT2/mTmG mice were treated with tamoxifen before and after pulmonary fibrosis was induced by Dox in food for 4 weeks. (B) Representative FACS plots show increased accumulation of WT1-drived myofibroblasts in Pre-/Post-Tam–treated TGFα/WT1CreERT2/mTmG mice compared with Pre-Tam–treated TGFα/WT1CreERT2/mTmG mice or control mice on Dox for 4 weeks. (C) Quantification of GFP-positive myofibroblasts in lung cultures of tamoxifen-treated TGFα/WT1CreERT2/mTmG mice or control mice on Dox for 4 weeks. (D) Immunofluorescence images show increased accumulation of WT1-derived mesenchymal cells residing in subpleura but not adventitia in tamoxifen-treated TGFα/WT1CreERT2/mTmG mice compared with control mice on Dox for 4 weeks. Scale bar: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts